Compound for use in and methods of treatment of fibrotic diseases

The use of compound 1 in the manufacture of a medicament for treating a patient in need of therapy using compound 1, characterized in that the treating comprises avoiding or contraindicating or discontinuing concomitant use or co-administration of nintedanib.

A method of administering treatment using compound 1 to a patient in need of therapy using compound 1 comprising administering the patient a therapeutically effective amount of compound 1, and, avoiding or contraindicating or discontinuing concomitant use or co-administration of nintedanib.

Compound 1 for use, use of compound 1 or method according to any of the preceding claims wherein the patient in need of therapy using compound 1 is currently undergoing treatment with nintedanib.

Compound 1 for use, use of compound 1 or method according to any of the preceding claims wherein the use or method comprises the step of discontinuing the use of or treatment with nintedanib prior to or at the same time as the step of starting compound 1 therapy.

Compound 1 for use, use of compound 1 or method according to any of the preceding claims wherein the use or method further comprises concomitant use or co-administration of pirfenidone.

Compound 1 for use, use of compound 1 or method according to any of the preceding claims wherein the use or method comprises discontinuing treatment with nintedanib and commencing treatment with pirfenidone.

Compound 1 for use, use of compound 1 or method according to any of the preceding claims wherein the patient in need of compound 1 therapy has pulmonary fibrosis, such as idiopathic pulmonary fibrosis (IPF) or progressive fibrosing interstitial lung disease (PF-ILD).

Compound 1 for use, use of compound 1 or method according to any of the preceding claims wherein compound 1 is administered at a total daily dosage of at least 25 to 300 mg.

Compound 1 for use, use of compound 1 or method according to any of the preceding claims wherein each dose of compound 1 administered is 25, 50 or 100 mg.

A package or kit comprising (i) compound 1, and (ii) a package insert, package label, instructions or other labelling comprising instructions to avoid or discontinue or contraindication of concomitant use or co-administration of nintedanib.